Overview

• Using single-cell sequencing, the team identified CA125 and TM4SF1 as biomarkers across diverse histologic variant bladder tumors.
• Engineered CAR-T cells recognizing TM4SF1 eradicated aggressive HV tumors in preclinical mouse models with high precision.
• Histologic variant bladder cancer accounts for nearly 25% of cases and its heterogeneity and exclusion from trials have limited treatment options.
• Published June 17 in Nature Communications, the study was funded by the NIH, Chan-Zuckerberg Biohub and dedicated urology foundations.
• Researchers are preparing to launch clinical trials to assess the safety and efficacy of the CAR-T therapy in human patients.